Centessa Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) was the recipient of unusually large options trading activity on Wednesday. Investors acquired 10,659 put options on the stock. This is an increase of 1,668% compared to the average volume of 603 put options.

Centessa Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ CNTA opened at $39.69 on Friday. The business has a 50-day moving average of $26.93 and a two-hundred day moving average of $25.45. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of -21.69 and a beta of 1.25. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $40.26. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, April 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on CNTA. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Guggenheim reissued a “neutral” rating on shares of Centessa Pharmaceuticals in a research report on Thursday. B. Riley Financial lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $40.00.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 349,073 shares of company stock worth $9,429,412 in the last ninety days. 7.09% of the stock is owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $36,000. T. Rowe Price Investment Management Inc. lifted its position in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN lifted its position in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Trending Headlines about Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly acquisition reported — Multiple outlets report Eli Lilly will acquire Centessa in a deal worth up to $7.8B; press coverage notes shareholders would receive roughly $38 in cash plus contingent value rights tied to potential upside, which sets a clear takeover premium/floor under the stock. LLY to Buy Centessa — Zacks
• Positive Sentiment: Large call buying — Reports show unusually high volume of call-option purchases, a bullish signal from derivatives traders that may reflect takeover-related arbitrage or speculative upside interest. Investors Purchase Calls — American Banking News
• Neutral Sentiment: Guggenheim reaffirmed “neutral” — Guggenheim left its rating unchanged, signaling no strong analyst upgrade in response to the takeover buzz. Guggenheim Reaffirms — TickerReport
• Neutral Sentiment: Leerink moved to “hold” but raised price target to $40 — A mixed note: downgrading the rating but nudging the target slightly above current market levels, reflecting uncertainty about deal dynamics or timing. Leerink Downgrade / PT — Benzinga
• Negative Sentiment: Multiple analyst downgrades — Several firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) cut ratings to hold from stronger stances, pressuring sentiment despite the takeover reports. Analyst Downgrades — Zacks Wolfe Research — American Banking News Needham — American Banking News
• Negative Sentiment: Shareholder investigations and class-action alerts — Two law firms announced probes into the proposed sale process and price adequacy, creating legal/transaction risk that can weigh on the stock and complicate closing. Monteverde & Associates — PR Newswire KSF Investigation — BusinessWire
• Negative Sentiment: Earnings miss — Centessa reported Q (EPS -$0.48) that missed consensus (~ -$0.38), an operational disappointment that adds near-term pressure independent of M&A news. Earnings Release — MarketBeat
• Negative Sentiment: Heavy put buying — Separately, unusual volume in put options (10,659 puts, a large jump vs. average) shows some participants betting on downside or using puts for hedging around the deal. (No direct link provided in feed.)

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.